Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nuclide Labeled TH-SC01 in Radiation Proctitis
NCT06925607Phase 1Not yet recruiting
- Sponsor
- Jiangsu Tuohong Kangheng Pharmaceutical Co., Ltd.
- Start
- Apr 2025
- Primary completion
- Mar 2026
- Modality
- Mesenchymal Stem Cells
01
Overview
Phase 1, open-label, single-arm trial of TH-SC01 in radiation proctitis, sponsored by Jiangsu Tuohong Kangheng Pharmaceutical Co., Ltd. Primary endpoint: Radioactive distribution. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
TH-SC01
03
Conditions
radiation proctitis
Beyond the preview
Go deeper on NCT06925607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06925607.